The latest in a string of deals into which the Belgian company Ablynx has entered is one with Boehringer Ingelheim signed on 7 September 2007. The global strategic alliance between the two companies is for the discovery, development and commercialisation of up to ten different therapeutics based on Ablynx#8217;s proprietary technology. This is the sixth collaboration that Ablynx has formed with a major pharma, and, for this small university spin-off company which has existed for only 6 years, signifies the potential of its technology: Ablynx is one of only a handful of firms pioneering miniature antibodies, or Nanobodies#174;, as they are termed by Ablynx. The article looks at Ablynx#8217;s mini-antibody platform and pipeline, and discusses the deals the company has made, including the two with Boehringer, as well as GlaxoSmithKline#8217;s recent acquisition of rival company Domantis.